Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: a systematic review and meta-analysis

Metastatic triple-negative breast cancer (TNBC) is a heterogeneous disease with poor prognosis [1] . Taxane or platinum-based chemotherapy (CT) have been first-line standard systemic treatment for most patients with metastatic TNBC. Bevacizumab in combination with CT, as maintenance therapy, is widely used in several countries despite lack of clear overall survival (OS) benefit [2,3,4] . Evading immune destruction is one of the hallmarks of cancer and the identification of escape mechanisms of cancer cells has resulted in the development of immune checkpoint inhibitors (ICI).

Source: Cancer Treatment Reviews - February 1, 2022 Category: Cancer & Oncology Authors: Guillermo Villacampa, Pablo Tolosa, Fernando Salvador, Rodrigo S ánchez-Bayona, Lorea Villanueva, Rodrigo Dienstmann, Eva Ciruelos, Tomas Pascual Source Type: research